EU Attack On Drug IP Practices Presents Challenges

By Ryan Davis

Law360, New York (December 01, 2008, 12:00 AM ET) -- The European Commission's report last week accusing major drug companies of working to delay or block the sale of generic versions of their medicines presents a number of challenges both for drugmakers and the commission, competition and intellectual property lawyers say.

The report, which consists of the preliminary findings of an investigation begun in January, criticized several widespread practices in the pharmaceutical industry, such as filing multiple patent applications for the same drug and settlement deals that require generics makers to stay out of the market...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles